The anti-PD 1 checkpoint inhibitor, pembrolizumab, continues to deliver impressive results in patients with advanced melanoma-producing long-lasting responses and improved overall survival, regardless of whether patients have been previously treated with ipilimumab.
The immunotherapy drug ipilimumab reduced the relative risk of cancer recurrence in the adjuvant setting by 25% compared to placebo for patients with high-risk, lymph-node positive melanoma.
Robert H. I. Andtbacka, MD, CM, from the Huntsman Cancer Institute, discusses OS findings from the phase III OPTiM study that explored T-VEC in patients with unresectable melanoma.
Lawrence Fong, MD, from the University of California, San Francisco, discusses the systemic antitumor effect and clinical response in a phase II trial of intratumoral electroporation of plasmid interleukin-12 in patients with advanced melanoma.
Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses two studies in BRAF-mutated colorectal cancer.
The third-generation EGFR inhibitor CO-1686 continues to demonstrate promising activity in patients with non–small cell lung cancer (NSCLC) who developed resistance after prior treatment with an EGFR tyrosine kinase inhibitor (TKI).
Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses the safety and response with plus erlotinib in patients with epidermal growth factor receptor mutant (EGFR MT) advanced non-small cell lung cancer (NSCLC).
Frontline therapy with bevacizumab (Avastin) or cetuximab (Erbitux) combined with either FOLFOX or FOLFIRI yielded a comparable survival benefit of approximately 29 months in patients with KRAS wild-type metastatic colorectal cancer
In what was described as "an almost unprecedented improvement in median survival," the addition of the chemotherapy drug docetaxel to standard hormone therapy prolonged life for men with newly diagnosed metastatic, hormone-sensitive prostate cancer by nearly 14 months.
A dual HER2-blockade strategy that added lapatinib to trastuzumab for the adjuvant treatment of women with early breast cancer failed to demonstrate a significant improvement in DFS over the standard therapy with trastuzumab alone.
John C. Byrd, MD, from The Ohio State University Comprehensive Cancer Center, discusses the promising findings from the phase III RESONATE trial that compared ofatumumab to ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia.
MPDL3280A reduced tumors in 43% of patients with previously treated PD-L1-positive metastatic bladder cancer, resulting in the first breakthrough therapy designation from the FDA for a treatment in this setting.
Adding the VEGFR-2 inhibitor ramucirumab to standard docetaxel improved overall survival by 1.4 months versus docetaxel alone in patients with advanced non–small cell lung cancer.
Mark D. Pegram, MD, from the Stanford University Medical Center, discusses a phase II study of margetuximab in patients with relapsed or refractory advanced breast cancer whose tumors express HER2 at the 2+ level by immunohistochemistry and lack evidence of HER2 gene amplification by FISH.
Combining the oral targeted agents olaparib and cediranib resulted in a near-doubling of median progression-free survival (PFS) among women with recurrent ovarian cancer in a phase II study highlighted Saturday during the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting.
Treatment with single-agent ibrutinib dramatically increased PFS by nearly 80% and significantly extended OS by 57% compared with ofatumumab in patients with relapsed or refractory CLL.
Lenvatinib, a novel multityrosine kinase inhibitor, is highly effective against differentiated thyroid cancer that has become resistant to standard RAI therapy.
Patients with less aggressive, HPV-positive oropharyngeal cancer can be effectively treated with a lower-dose radiation regimen depending upon their response to combination induction therapy.
Denise A. Yardley, MD, hematologist/oncologist, Sarah Cannon Research Institute discusses a pilot study to assess safety, pharmacokinetics, and effects on circulating estrogens in women with advanced hormone-positive breast cancer when given enzalutamide plus exemestane.
Adding goserelin to chemotherapy for women with early-stage hormone receptor (HR)-negative breast cancer helps both to preserve their fertility and to prolong their survival.
A phone-based intervention that offers practical tools to help family caregivers support their loved one with advanced cancer-as well as emphasizing the importance of maintaining a healthy lifestyle themselves-resulted in less caregiver depression and better quality of life, according to the findings of a new study presented May 30 at the 50th Annual ASCO Meeting in Chicago.
The dosing frequency of zoledronic acid can be reduced by 67% without compromising efficacy and safety in women with breast cancer and bone metastases.
Maha Hussain, MD, from the University of Michigan Comprehensive Cancer Center, discusses the possibility of ETS gene fusions acting as a predictive biomarker for prostate cancer.
For patients with less than a year to live, the discontinuation of statins may increase the median time-to-death and improve quality of life.
Silvia Formenti, MD, The Sandra and Edward H. Meyer Professor of Radiation Oncology chair, Radiation Oncology, NYU Langone Medical Center, associate director, Radiation Oncology, Perlmutter Cancer Center at NYU Langone, discusses a trial that examines concurrent adjuvant systemic therapy and accelerated radiotherapy in triple-negative breast cancer (TNBC)
Anna C. Pavlick, DO, associate professor, Hematology and Medical Oncology, medical director, Clinical Trials Office, Perlmutter Cancer Center at NYU Langone, discusses a phase II trial exploring low-dose cyclophosphamide and ipilimumab in metastatic melanoma.
Jason J. Luke, MD, instructor, Department of Medicine, Harvard School of Medicine, staff physician, medical oncologist- melanoma, Dana-Farber Cancer Institute, discusses the controversy behind the COMBI-d trial results.
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses a long-term safety analysis of the COU-AA-302 study, which he presented at the 2014 AUA Annual Meeting.
Deepak A. Kapoor, MD, from Integrated Medical Professionals, PLLC, discusses the inclusion of radium-223 in the AUA guideline for castration resistant prostate cancer (CRPC).
Analysis of trends in prostate-specific antigen (PSA) dynamics suggested that PSA growth rates, as well as the amount of PSA-level increase due specifically to cancer, might offer a means of distinguishing aggressive, potentially fatal prostate cancer from clinically inconsequential tumors.
